Renovorx phase iii open label tiger-pac interim analysis shows promising data that support continued clinical investigation of renovogemtm as a treatment option for locally advanced pancreatic cancer

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced promising interim data in the phase iii open label tiger-pac clinical trial. the study is investigating the company's first product candidate, renovogem, as a potential treatment option in locally advanced pancreatic cancer (“lapc”).
RNXT Ratings Summary
RNXT Quant Ranking